ReachMD

09/10/2026

When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease

09/10/2026

Why is pediatric FSGS often different from adult disease?

Children with FSGS frequently present with nephrotic syndrome, and by the time a biopsy confirms the diagnosis, steroid resistance has already been established. Experts discuss how this unique clinical presentation, combined with advances in genetic testing, is reshaping our understanding of pediatric FSGS and informing patient evaluation.

Explore the key takeaways from this discussion: https://ow.ly/vuMH50ZFbTm

Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported...

09/10/2026

Women’s health is evolving fast, with new treatments, updated guidelines, and important conversations constantly emerging.

WHAV 2026 offers a community-driven, collaborative environment where clinicians can explore the latest advances in women’s health and engage directly with expert faculty and their peers.

Don’t miss the conversation. Claim your spot at WHAV 2026 today.

Register for the NYC event: https://ow.ly/mm3n50ZLHzX

Sign up to attend in Pasadena: https://ow.ly/mm3n50ZLHzX

09/10/2026

How do you decide when to escalate treatment in moderate to severe atopic dermatitis? Join a live virtual webinar on September 24 to explore disease burden, treatment selection, and individualized care. Register now: https://ow.ly/x7sc50ZKXaJ

A CME/CE-accredited activity developed by GLC.

09/10/2026

Tomorrow: Join experts for a live discussion on current and emerging treatment approaches in CLL/SLL, including sequencing considerations and evolving BTK- and BCL2-directed therapies.

Register now: https://ow.ly/uSiX50ZzWSP

A CME/CE-accredited activity developed by GLC.

09/09/2026

Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care

09/09/2026

When disease progresses after frontline EGFR-TKI therapy, what factors should guide treatment decisions for patients with EGFR-mutated advanced NSCLC?

During this live webinar series, expert faculty will review the evolving role of TROP2-directed ADCs and the clinical evidence supporting their use in the post-TKI setting. The program will also explore practical approaches to identifying appropriate candidates based on clinical and molecular characteristics, along with proactive strategies for recognizing and managing class-specific toxicities.

Join the conversation and gain case-based insights on integrating TROP2-directed ADCs into personalized care: https://ow.ly/3Hz150ZBCTA

A CME/CE-accredited activity developed by GLC.

09/08/2026

How has genetics changed our understanding of FSGS?

Genetic causes are increasingly recognized as an important contributor to FSGS, particularly in children. In this discussion, experts review the growing role of genetics in disease classification and explain how a deeper understanding of etiology is helping to refine how clinicians think about FSGS.

Learn more about the evolving science behind FSGS: https://ow.ly/VsuO50ZKIOP

09/08/2026

One week to go before our first webinar in the series. Join expert faculty for a live discussion on perioperative immunotherapy in resectable, locally advanced HNSCC.
The program will explore findings from KEYNOTE-689 and NIVOPOSTOP, patient selection, and multidisciplinary management.

Save your spot: https://ow.ly/hujn50ZBzPE

A CME/CE-accredited activity developed by GLC.

09/06/2026

One week until our live WCLC 2026 satellite symposium on immunotherapy-resistant advanced squamous . Hear expert perspectives on CTLA-4-targeted approaches, sequencing decisions, and individualized treatment planning.

Join us live in Seoul for complimentary coffee and expert perspectives!

Save your seat: https://ow.ly/xg6t50ZAIw2

A CME/CE-accredited activity developed by GLC.